Literature DB >> 20875388

N-acetylcysteine in critically ill patients undergoing contrast-enhanced computed tomography: a randomized trial.

K E A Burns, F Priestap, C Martin.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20875388     DOI: 10.5414/cnp74323

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


× No keyword cloud information.
  4 in total

Review 1.  The effectiveness of N-Acetylcysteine in preventing contrast-induced nephropathy in patients undergoing contrast-enhanced computed tomography: a meta-analysis of randomized controlled trials.

Authors:  Mei-Yi Wu; Hui-Fen Hsiang; Chung-Shun Wong; Min-Szu Yao; Yun-Wen Li; Chao-Ying Hsiang; Chyi-Huey Bai; Yung-Ho Hsu; Yuh-Feng Lin; Ka-Wai Tam
Journal:  Int Urol Nephrol       Date:  2013-01-03       Impact factor: 2.370

Review 2.  Prevention of contrast-induced AKI: a review of published trials and the design of the prevention of serious adverse events following angiography (PRESERVE) trial.

Authors:  Steven D Weisbord; Martin Gallagher; James Kaufman; Alan Cass; Chirag R Parikh; Glenn M Chertow; Kendrick A Shunk; Peter A McCullough; Michael J Fine; Maria K Mor; Robert A Lew; Grant D Huang; Todd A Conner; Mary T Brophy; Joanne Lee; Susan Soliva; Paul M Palevsky
Journal:  Clin J Am Soc Nephrol       Date:  2013-05-09       Impact factor: 8.237

Review 3.  N-acetylcysteine for sepsis and systemic inflammatory response in adults.

Authors:  Tamas Szakmany; Balázs Hauser; Peter Radermacher
Journal:  Cochrane Database Syst Rev       Date:  2012-09-12

4.  Effectiveness of contrast-associated acute kidney injury prevention methods; a systematic review and network meta-analysis.

Authors:  Khalid Ahmed; Terri McVeigh; Raminta Cerneviciute; Sara Mohamed; Mohammad Tubassam; Mohammad Karim; Stewart Walsh
Journal:  BMC Nephrol       Date:  2018-11-13       Impact factor: 2.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.